Recently Viewed
Clear All$70.98
$0.00 (0.00%)As on 15-Nov-2024 09:30EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$3,628 Mln
Revenue (TTM)
$432 Mln
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5.5
Industry P/E
44.86
EV/EBITDA
381.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.1
Face value
--
Shares outstanding
51,109,200
CFO
$-280.21 Mln
EBITDA
$-275.12 Mln
Net Profit
$-348.65 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Axonics Modulation Technologies Inc (AXNX)
| 14.1 | 1.1 | 3.4 | 25.3 | 5.3 | 19.6 | -- |
|
BSE Sensex*
| -8.4 | -1.7 | -8.7 | 6.1 | 9.0 | 9.3 | 12.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
Axonics Modulation Technologies Inc (AXNX)
| -0.5 | 11.7 | 12.2 | 80.2 | 83.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive... bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. As of November 15, 2024, Axonics, Inc. operates as a subsidiary of Boston Scientific Corporation. Read more
CEO & Director
Mr. Raymond W. Cohen
CEO & Director
Mr. Raymond W. Cohen
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Axonics Modulation Technologies Inc (AXNX) is $70.98 (NASDAQ) as of 15-Nov-2024 09:30 EDT. Axonics Modulation Technologies Inc (AXNX) has given a return of 5.29% in the last 3 years.
Since, TTM earnings of Axonics Modulation Technologies Inc (AXNX) is negative, P/E ratio is not available.
The P/B ratio of Axonics Modulation Technologies Inc (AXNX) is 5.46 times as on 15-Nov-2024, a 82 premium to its peers’ median range of 3.00 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-504.98
|
4.82
|
|
2022
|
-52.85
|
5.53
|
|
2021
|
-31.45
|
5.22
|
|
2020
|
-35.43
|
6.77
|
|
2019
|
-10.53
|
4.60
|
The 52-week high and low of Axonics Modulation Technologies Inc (AXNX) are Rs -- and Rs -- as of 09-Apr-2026.
Axonics Modulation Technologies Inc (AXNX) has a market capitalisation of $ 3,628 Mln as on 15-Nov-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Axonics Modulation Technologies Inc (AXNX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.